Drug intelligence / Profile preview

strontium-85

Development stage: Unknown
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intramuscular, Intravenous

Overview

Strontium-85 is a radioactive isotope with a half-life of 64.84 days that emits gamma-rays. It is used in medicine primarily as a diagnostic radiopharmaceutical for bone imaging. Due to its chemical similarity to calcium, strontium-85 is metabolized by the body in a manner closely paralleling calcium, leading to its uptake in bone tissue. This property allows doctors to use strontium-85 injections for detecting areas of increased calcium turnover, such as in bone fractures, tumors, osteomyelitis, Paget's disease, and metastatic bone disease, through external scintillation counting or automatic scintillation scanning. It is typically administered as a strontium chloride solution.

Other names: Sr-85Sr85Sr 85

Beyond the preview

Go deeper on strontium-85.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on strontium-85.

Explore the full profile